Sugammadex | CAS#343306-71-8 | 343306-79-6 | SRBA

MedKoo Cat#: 319991 | Name: Sugammadex

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sugammadex is an agent for reversal of neuromuscular blockade by the agent rocuronium in general anaesthesia. It is the first selective relaxant binding agent (SRBA). Sugammadex is a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periphery. This gamma cyclodextrin has been modified from its natural state by placing eight carboxyl thio ether groups at the sixth carbon positions. These extensions extend the cavity size allowing greater encapsulation of the rocuronium molecule. These negatively charged extensions electrostatically bind to the quaternary nitrogen of the target as well as contribute to the aqueous nature of the cyclodextrin.

Chemical Structure

Sugammadex

CAS#343306-71-8 (free form)

Theoretical Analysis

MedKoo Cat#: 319991

Name: Sugammadex

CAS#: 343306-71-8 (free form)

Chemical Formula: C72H112O48S8

Exact Mass: 2000.4089

Molecular Weight: 2002.12

Elemental Analysis: C, 43.19; H, 5.64; O, 38.36; S, 12.81

Price and Availability

Size	Price	Availability
100mg	USD 250.00	2 Weeks
200mg	USD 450.00	2 Weeks
500mg	USD 750.00	2 Weeks
1g	USD 1,250.00	2 Weeks
2g	USD 2,150.00	2 Weeks
5g	USD 4,250.00	2 Weeks
10g	USD 7,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

343306-71-8 (free form) 343306-79-6 (sodium)

Synonym

Org25969; Org-25969; Org 25969; Sugammadex; trade name: Bridion.

IUPAC/Chemical Name

6A,6B,6C,6D,6E,6F,6G,6H-octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-γ-cyclodextrin

InChi Key

WHRODDIHRRDWEW-XJDGUENZSA-N

InChi Code

InChI=1S/C72H112O48S8/c73-33(74)1-9-121-17-25-57-41(89)49(97)65(105-25)114-58-26(18-122-10-2-34(75)76)107-67(51(99)43(58)91)116-60-28(20-124-12-4-36(79)80)109-69(53(101)45(60)93)118-62-30(22-126-14-6-38(83)84)111-71(55(103)47(62)95)120-64-32(24-128-16-8-40(87)88)112-72(56(104)48(64)96)119-63-31(23-127-15-7-39(85)86)110-70(54(102)46(63)94)117-61-29(21-125-13-5-37(81)82)108-68(52(100)44(61)92)115-59-27(19-123-11-3-35(77)78)106-66(113-57)50(98)42(59)90/h25-32,41-72,89-104H,1-24H2,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t25?,26?,27?,28?,29?,30?,31?,32?,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72?/m0/s1

SMILES Code

O[C@H]1[C@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O)[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@H](O[C@@H]5[C@@H](O)[C@H](O)[C@H](O6)C(CSCCC(O)=O)O5)C(CSCCC(O)=O)O4)C(CSCCC(O)=O)O3)C(CSCCC(O)=O)O2)C(CSCCC(O)=O)O[C@@H]1O[C@H]7[C@@H](O)[C@H](O)[C@@H](O[C@H]8[C@@H](O)[C@H](O)[C@@H](O[C@H]9[C@@H](O)[C@H](O)C6OC9CSCCC(O)=O)OC8CSCCC(O)=O)OC7CSCCC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 343306-71-8 (free form); 343306-79-6 (sodium salt) Sugammadex was discovered by the pharmaceutical company Organon at the Newhouse Research Site in Scotland. Organon was acquired by Schering-Plough in 2007; Schering-Plough merged with Merck in 2009. Sugammadex is now owned and sold by Merck. The US Food and Drug Administration (FDA) initially rejected Schering-Plough's New Drug Application for sugammadex in 2008,[2] but finally approved the medication for use in the United States on December 15, 2015. Sugammadex was approved for use in the European Union on July 29, 2008.

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Sugammadex is a selective relaxant binding agent for complexing aminosteroid nonpolarizing neuromuscular blockers.

In vitro activity:

Sugammadex has protective and antioxidant properties on cytotoxicity and could be an effective supplement for neurodegenerative diseases such as Alzheimer and Parkinson diseases. Sugammadex at concentrations of 50 and 100 μg/mL significantly enhanced the cell viability in C6 glioma cells after the cytotoxicity induced by glutamate. Sugammadex considerably decreased the levels of nNOS NO and TOS and the number of apoptotic cells and increased the level of TAS. Reference: Fundam Clin Pharmacol. 2023 Aug;37(4):786-793. https://pubmed.ncbi.nlm.nih.gov/36880372/

In vivo activity:

In early chick embryos, sugammadex exposure correlated with decreased embryo size, somite counts, and increased Caspase-3 H-Score, suggesting developmental delays and higher neural tube defect incidence. These findings indicate that sugammadex crossing the placenta may disrupt embryonic development, with effects increasing dose-dependently. Reference: Microsc Res Tech. 2024 Mar;87(3):506-515. https://pubmed.ncbi.nlm.nih.gov/37933747/

Preparing Stock Solutions

The following data is based on the product molecular weight 2,002.12 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Dirik H, Joha Z. Investigation of the effect of sugammadex on glutamate-induced neurotoxicity in C6 cell line and the roles played by nitric oxide and oxidative stress pathways. Fundam Clin Pharmacol. 2023 Aug;37(4):786-793. doi: 10.1111/fcp.12890. Epub 2023 Mar 14. PMID: 36880372. 2. Fliszár-Nyúl E, Csepregi R, Benkovics G, Szente L, Poór M. Testing the Protective Effects of Sulfobutylether-Βeta-Cyclodextrin (SBECD) and Sugammadex against Chlorpromazine-Induced Acute Toxicity in SH-SY5Y Cell Line and in NMRI Mice. Pharmaceutics. 2022 Sep 7;14(9):1888. doi: 10.3390/pharmaceutics14091888. PMID: 36145637; PMCID: PMC9504268. 3. Büyükerkmen E, Atay E, Firat F, Yüksek A, Bilir A, Albaş Kurt G, Saritaş A. Effect of sugammadex administration on neural tube development in 48-h chick embryos. Microsc Res Tech. 2024 Mar;87(3):506-515. doi: 10.1002/jemt.24452. Epub 2023 Nov 7. PMID: 37933747. 4. Park HY, Choi HR, Kim YB, Oh SK, Kim T, Yang HS, In J. Chronic exposure to dexamethasone may not affect sugammadex reversal of rocuronium-induced neuromuscular blockade: an in vivo study on rats. Anesth Pain Med (Seoul). 2023 Jul;18(3):275-283. doi: 10.17085/apm.23021. Epub 2023 Jul 14. PMID: 37468197; PMCID: PMC10410550.

In vitro protocol:

In vivo protocol:

1. Büyükerkmen E, Atay E, Firat F, Yüksek A, Bilir A, Albaş Kurt G, Saritaş A. Effect of sugammadex administration on neural tube development in 48-h chick embryos. Microsc Res Tech. 2024 Mar;87(3):506-515. doi: 10.1002/jemt.24452. Epub 2023 Nov 7. PMID: 37933747. 2. Park HY, Choi HR, Kim YB, Oh SK, Kim T, Yang HS, In J. Chronic exposure to dexamethasone may not affect sugammadex reversal of rocuronium-induced neuromuscular blockade: an in vivo study on rats. Anesth Pain Med (Seoul). 2023 Jul;18(3):275-283. doi: 10.17085/apm.23021. Epub 2023 Jul 14. PMID: 37468197; PMCID: PMC10410550.

1: Radkowski P, Derkaczew MA, Jacewicz MA, Onichimowski D. The Dosage of Muscle Relaxants in Morbidly Obese Patients in Daily Practice - A Narrative Review. Int J Gen Med. 2024 Sep 14;17:4055-4060. doi: 10.2147/IJGM.S474221. PMID: 39295858; PMCID: PMC11410373. 2: Postaci A, Durgut R, Aytac BG, Ceyhan M. Effect of sugammadex with neostigmine on postoperative bowel function and on recovery of neuromuscular functions: A randomized controlled trial. Medicine (Baltimore). 2024 Sep 13;103(37):e39623. doi: 10.1097/MD.0000000000039623. PMID: 39287249; PMCID: PMC11404935. 3: Wang Y, Qu Y, Jiang Y, Li Z, Hou X, Yang L, Zhao L, Xiong X, Xu M. Magnetic solid-phase extraction coupled with LC-MS/MS methods for the simple extraction and rapid determination of sugammadex in human plasma. Anal Methods. 2024 Sep 16. doi: 10.1039/d4ay01185f. Epub ahead of print. PMID: 39279656. 4: Palermo J, Tingey S, Khanna AK, Segal S. Evaluation and Prevention of Perioperative Respiratory Failure. J Clin Med. 2024 Aug 27;13(17):5083. doi: 10.3390/jcm13175083. PMID: 39274295; PMCID: PMC11396761. 5: Dejoux A, Zhu Q, Ganneau C, Goff OR, Godon O, Lemaitre J, Relouzat F, Huetz F, Sokal A, Vandenberghe A, Pecalvel C, Hunault L, Derenne T, Gillis CM, Iannascoli B, Wang Y, Rose T, Mertens C, Nicaise-Roland P; NASA Study Group; England P, Mahévas M, de Chaisemartin L, Le Grand R, Letscher H, Saul F, Pissis C, Haouz A, Reber LL, Chappert P, Jönsson F, Ebo DG, Millot GA, Bay S, Chollet- Martin S, Gouel-Chéron A, Bruhns P. Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models. Sci Transl Med. 2024 Sep 11;16(764):eado4463. doi: 10.1126/scitranslmed.ado4463. Epub 2024 Sep 11. PMID: 39259810. 6: Brown SES, Meyer M, Meyer A, Cassidy R, Zhao X, Wagner D, Wetzel L, Colquhoun DA. Weight-Based Standardized Sugammadex Dosing in Pediatrics: A Quality Improvement Initiative to Improve Compliance with Dosing Guidelines and Reduce Waste and Cost. Anesthesiol Res Pract. 2024 Aug 24;2024:6049114. doi: 10.1155/2024/6049114. PMID: 39221435; PMCID: PMC11366054. 7: Rodek P, Mędrala W, Chrobak J, Barabasz-Gembczyk A, Alli-Balogun B, Kucia K. Around anesthesia: anesthetic aspects of electroconvulsive treatment in the light of the latest reports - review article. Psychiatr Pol. 2024 Feb 20:1-11. English, Polish. doi: 10.12740/PP/OnlineFirst/174768. Epub ahead of print. PMID: 39217425. 8: Kaneko S, Makino M, Kawazoe Y, Sato S, Iwamizu A, Narimatsu R, Yamaguchi H, Miyagawa K, Ichinomiya T, Murata H, Yoshitomi O, Hara T. A novel stimulating electrode attachment method designed to maintain electromyography-based neuromuscular monitoring detectability during laparoscopic surgery: a single- center randomized, double-blind, controlled pilot study. J Anesth. 2024 Aug 31. doi: 10.1007/s00540-024-03397-3. Epub ahead of print. PMID: 39214897. 9: Maqusood S, Bele A, Verma N, Dash S, Bawiskar D. Sugammadex vs Neostigmine, a Comparison in Reversing Neuromuscular Blockade: A Narrative Review. Cureus. 2024 Jul 29;16(7):e65656. doi: 10.7759/cureus.65656. PMID: 39205735; PMCID: PMC11352768. 10: Radkowski P, Krupiniewicz KJ, Suchcicki M, Machoń NJ, Cappello S, Szewczyk M, Wolska JM, Stompór T. Navigating Anesthesia: Muscle Relaxants and Reversal Agents in Patients with Renal Impairment. Med Sci Monit. 2024 Aug 27;30:e945141. doi: 10.12659/MSM.945141. PMID: 39188037; PMCID: PMC11365435. 11: Miyazaki Y, Suzuki K, Yamakawa K, Sunaga H. Sugammadex Versus Neostigmine for Bariatric Surgery: Methodological Concerns. Anesth Analg. 2024 Aug 23. doi: 10.1213/ANE.0000000000007194. Epub ahead of print. PMID: 39178304. 12: Lin XN, Zeng YJ, Cao S, Jing XB. A real-world pharmacovigilance study of cardiac adverse events induced by sugammadex in the FDA adverse event reporting system. Expert Opin Drug Saf. 2024 Aug 29:1-9. doi: 10.1080/14740338.2024.2396645. Epub ahead of print. PMID: 39174878. 13: Choi ES, Lee J, Lee JH, Kim JH, Han SH, Park JW. Effects of neuromuscular block reversal with neostigmine/glycopyrrolate versus sugammadex on bowel motility recovery after laparoscopic colorectal surgery: A randomized controlled trial. J Clin Anesth. 2024 Nov;98:111588. doi: 10.1016/j.jclinane.2024.111588. Epub 2024 Aug 21. PMID: 39173241. 14: Tan L, Pan Z, Zeng Q, Peng Y, Yang F, Lu D. The knowledge profile, attitudes, and perioperative management of Chinese anesthesiologists towards patients with obstructive sleep apnea: a cross-sectional survey. Sleep Breath. 2024 Aug 22. doi: 10.1007/s11325-024-03119-9. Epub ahead of print. PMID: 39172349. 15: Weerasuriya S, Seddon D, Salota V. Asystolic cardiac arrest secondary to sugammadex administration in a young patient. Anaesthesiol Intensive Ther. 2024;56(2):160-163. doi: 10.5114/ait.2024.141235. PMID: 39166508; PMCID: PMC11284579. 16: Samad M, Sutherland M, Ganier D Jr, Broussard D, Koveleskie J, Nossaman VE, Nossaman BD. Perioperative efficiency of sugammadex following minimally invasive gastric sleeve surgery: A superiority trial. J Perioper Pract. 2024 Aug 12:17504589241267859. doi: 10.1177/17504589241267859. Epub ahead of print. PMID: 39133158. 17: Frenkel M, Lien CA. Eliminating residual neuromuscular blockade: a literature review. Ann Transl Med. 2024 Aug 1;12(4):65. doi: 10.21037/atm-23-1743. Epub 2024 May 14. PMID: 39118951; PMCID: PMC11304418. 18: Fukasawa R, Oishi A, Nemoto C, Inoue S. A case of opioid-induced rigidity requiring naloxone administration at the time of anesthesia emergence. JA Clin Rep. 2024 Aug 1;10(1):47. doi: 10.1186/s40981-024-00732-1. PMID: 39088183; PMCID: PMC11294279. 19: Kiyama S. Reversing the triad of anaesthesia in a cannot intubate, cannot oxygenate emergency: a panacea for airway emergencies? Comment on Br J Anaesth 2024; 133: 190-2. Br J Anaesth. 2024 Jul 26:S0007-0912(24)00423-9. doi: 10.1016/j.bja.2024.06.040. Epub ahead of print. PMID: 39068118. 20: Brown SES, Cassidy R, Zhao X, Nause-Osthoff R, Wade M, Wagner D, Haydar B, Chimbira W, Kheterpal S, Colquhoun DA. Impact of Sugammadex Introduction on Using Neuromuscular Blockade and Endotracheal Intubation in a Pediatric Hospital: A Retrospective, Observational Cross-Sectional Study. Anesth Analg. 2024 Jul 26. doi: 10.1213/ANE.0000000000007048. Epub ahead of print. PMID: 39058621.